Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc.

LFCRยทNASDAQ

$5.67

+1.5%
HealthcareDrug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

At a Glance

Live Snapshot
Market Cap$212.68M
EPS-1.2700
P/E Ratio-4.46
Earnings Date07/31/2026
Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. Fair Value Envelope

LFCR ยท NASDAQ

Our analysis suggests that LFCR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.67, this represents a potential HIDDEN relative to our calculated worth for Lifecore Biomedical, Inc..

Intrinsic Value
Current Price: $5.67

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$70.0M
+ Cash & Equivalents$8.3M
Firm Value-$61.8M
- Debt$130.8M
Equity Value-$192.6M
/ Shares Outstanding37,398,190B
DCF Value-$5
OVERVALUED BY 191%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$257.3K
-$321.4K
-$401.4K
-$501.4K
-$626.2K
-$782.2K
-$977.0K
-$1.2M
-$1.5M
-$1.9M
Maintenance CapEx
-$3.4M
-$4.2M
-$5.2M
-$6.5M
-$8.2M
-$10.2M
-$12.7M
-$15.9M
-$19.9M
-$24.8M
Owner Earnings
-$3.6M
-$4.5M
-$5.6M
-$7.0M
-$8.8M
-$11.0M
-$13.7M
-$17.1M
-$21.4M
-$26.7M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$3.3M
-$3.9M
-$4.5M
-$5.2M
-$6.0M
-$6.9M
-$8.0M
-$9.2M
-$10.7M
-$12.4M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.